Early discontinuation of biological therapy among inflammatory bowel disease patients in Bahrain: Real world experience.

ABSTRACT:

Background

Despite the effectiveness of several biological agents in the treatment of inflammatory bowel disease (IBD), some patients respond better than others. Such discrepancies are often evident early in the treatment course. The aim of this study is to identify the risks and assess the rate of early biological discontinuation (BD) among IBD patients.

Methods

In this retrospective cohort study conducted in Bahrain all IBD patients who were administered biological agents between June 2009 and June 2019 were included. Medical records were reviewed to collect study data and confirm IBD diagnoses. Early discontinuation of biological agents was defined by discontinuation of a biological agent (within 6 months from administration). Montreal classification was used to classify

SUBMITTER: Abdulla M 

PROVIDER: S-EPMC9212118 | biostudies-literature | 2022 May-Jun

REPOSITORIES: biostudies-literature